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Muscle mass and density assessed from CT-images at the L3 level are prognostic for survival and predict 35 
toxicity in cancer patients. However, L3 is not always included on routine CT-scans. We aimed to investigate 36 
whether images at the Th4 level may be used instead. 37 
 38 
Methods 39 
Patients from three chemotherapy trials in advanced NSCLC were eligible (n=1305). Skeletal muscle area 40 
(cm2), skeletal muscle index (SMI, cm2/m2) and skeletal muscle density (SMD) at Th4 and L3 levels were 41 
assessed from baseline CT-scans. SMI and SMD at the Th4 and L3 level were transformed into z-scores 42 
and the agreement between scores was investigated by Bland-Altman plots and estimated by intra-class 43 
correlation analyses. Linear regression was used to test if Th4 SMI and SMD z-scores predicted L3 SMI and 44 
SMD z-scores.  45 
 46 
Results 47 
CT-images from 401 patients were analyzable at both levels. There was a moderate agreement between 48 
Th4 and L3 SMI z-scores with an intra-class correlation of 0.71 (95% CI 0.64–0.77) for men and 0.53 (95% 49 
CI 0.41–0.63) for women. Regression models predicting L3 SMI z-scores from Th4 SMI z-scores showed 50 
coefficients of 0.71 (95% CI 0.62-0.80) among men and 0.53 (95% CI 0.40-0.66) among women. R-squares 51 
were 0.51 and 0.28 respectively, indicating moderate agreement. A similar, moderate agreement between 52 
Th4 and L3 SMD z-scores was observed. 53 
 54 
Conclusion 55 
There was only moderate agreement between muscle measures from Th4 and L3 levels, indicating that 56 











Changes in human body composition related to aging and disease is gaining increasing interest. A particular 66 
focus has been rendered to muscle wasting and thereby loss of lean body mass (LBM). In aging, muscular 67 
depletion is associated with frailty and several negative health outcomes, including mortality.1, 2 In cancer 68 
populations, an increasing body of evidence links this feature to cachexia,3 worse survival,4-7 and increased 69 
risk of toxicity from systemic cancer therapy.8-12 Associations with postoperative infections and delayed 70 
recovery after surgery for colorectal cancer have also been reported.13 Muscle wasting may occur in obese 71 
patients (sarcopenic obesity) as well as in those who are normal or underweight. It is, however, frequently 72 
undetected since both weight and body mass index (BMI) are poor indicators of LBM.14 73 
There are several options for body composition assessment, including bioelectrical impedance 74 
analyses (BIA), dual energy X-ray absorptiometry (DXA) and analyses of computed tomography (CT) 75 
images.15 The latter method is particularly convenient in oncology settings due to frequent, routine CT-76 
imaging for diagnosis, staging, treatment evaluation and follow-up. In contrast to BIA and DXA, CT images 77 
provide specific details on muscle characteristics, adipose tissues and organs. Furthermore, skeletal muscle 78 
area quantified from a single CT slice at the third lumbar level (L3) is closely correlated to the estimated total 79 
lean body skeletal muscle mass (LBM).15, 16 Thus, utilizing CT images at the L3 level to assess body 80 
composition has become the gold standard in studies on cancer patients.3, 17 81 
CT based assessment makes it possible to measure skeletal muscle radiodensity (SMD) in addition 82 
to muscle mass. SMD is expressed as the mean Hounsfield Units (HU) of the measured cross sectional 83 
muscle area. Low values reflect increased fat deposits,18 are associated with older age,19, 20 and when 84 
measured at the lumbar level, they are also linked to worse survival in cancer patients.7, 21 In non-cancer 85 
populations, both SMD- and age-related differences between muscle groups have been found, indicating 86 
that the underlying etiological factors for muscle wasting may not affect all muscles similarly.19 87 
In non-small cell lung cancer (NSCLC), cachexia and muscle wasting are common and associated 88 
with worse prognosis and increased risk of treatment toxicity.7, 12, 22 However, diagnostic work-up of these 89 
patients is usually restricted to a CT-scan of the thorax and upper abdomen which often does not include the 90 
L3 level. Thus, CT-images at the fourth thoracic level (Th4) have been used to assess skeletal muscle mass 91 
and its relation to survival in lung cancer patients.23, 24 There is, however, limited knowledge about the 92 
agreement between muscle-measures at the L3 and at Th4 level,25 and none have compared muscular SMD 93 
at these levels in cancer patients. Based on data from three Norwegian randomized controlled trials (RCT) 94 
comparing first line chemotherapy regimens in advanced non-small cell lung cancer (NSCLC),26-28 we aimed 95 




Study sample 98 
The trials which this study is based upon were conducted from 2003 to 2009, and the main inclusion criteria 99 
were: Chemonaïve patients, age ≥18 years, stage IIIB/IV NSCLC and performance status (PS) 0-2. In all 100 
trials, the diagnostic work-up included a CT scan of the thorax and upper abdomen obtained within four 101 
weeks before chemotherapy commenced. These CT scans were collected retrospectively for assessment of 102 
LBM. For the present study, we included patients if the baseline CT-scan included analysable images both at 103 
the Th4 and L3 levels. 104 
 105 
Body composition assessments  106 
The diagnostic CT scans were analysed using Slice-O-Matic software (v.4.3 Tomovision, Montreal Canada) 107 
by three similarly trained observers blinded for other patient data. The first image in the caudal direction 108 
where both vertebral transverse processes were visible was used to manually outline the skeletal muscle 109 
tissue at the Th4 and L3 level, respectively. Based on pre-established thresholds of Hounsfield Units (HU) in 110 
the range of –29 to + 150 HU,15, 16 the cross-sectional areas (cm2) of the outlined muscle tissues at the Th4 111 
and L3 levels were automatically calculated by the software, normalised for stature (height squared), and 112 
expressed as Th4 and L3 skeletal muscle index (Th4 SMI, cm2/m2 and L3 SMI, cm2/m2). Optimally the whole 113 
circumference of the body should be included in the images at the L3 and Th4 levels to enable an exact 114 
quantification of the respective tissue areas. In some patients, parts of the muscular tissue were missing on 115 
the CT scans. If less than half of the circumference was missing, the total area was estimated by doubling 116 
the area of the opposite half of the body. If more than half of the circumference was missing, no 117 
quantification was possible and the patient was excluded from the analyses. SMD was assessed as the 118 
mean HU of the entire cross sectional muscle area at levels Th4 and L3.  119 
The patients’ BMI (weight (kg)/height (m2) were calculated based on baseline data from the RCTs. 120 
No systematic registration of weight loss at baseline was conducted, hence we used appetite loss registered 121 
on the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 122 
(EORTC QLQ-C30) as a supplementary indicator of nutrition status.  123 
 124 
Statistics 125 
Data from all RCTs were analysed jointly. Body composition measures were compared between men and 126 
women by independent sample t-tests, and all analyses investigating agreement between measures at the 127 
Th4 and L3 level were done for each gender separately.  128 
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 First, we investigated the agreement between the L3 skeletal muscle area, SMI and SMD and the 129 
corresponding measures at the Th4 level using scatterplots. Then, the SMI and SMD from both levels were 130 
transformed into z-scores, separately for men and women. The agreement between Th4 SMI z-scores and 131 
L3 SMI z-scores were investigated by Bland-Altman diagrams with locally fitted smooth (loess) curves, and 132 
by intraclass correlation. Whether Th4 SMI and SMD z-scores could predict L3 SMI and SMD z-scores were 133 
tested using linear regression. Finally, we tested the precision with which individual missing L3 SMI and SMD 134 
values could be estimated by using the patients’ z-scores from the corresponding Th4 SMI and SMD values. 135 
L3 SMI was recomputed using the mean L3 SMI for the cohort + SD x Th4 SMI z-score. The L3 SMD was 136 
recomputed similarly. The agreement between actual and recomputed L3 SMI and SMD were then 137 
examined by scatter plots.   138 
 All p-values were two-sided and p-values < 0.05 were used to define statistical significance. The 139 
statistical analyses were performed using IBM SPSS version 18 (IBM Corporation, Armonk, NY, USA). 140 
 141 
Ethics  142 
The study was performed according to the Helsinki declaration and approved by the Regional Committee for 143 
Medical and Health Research Ethics in South-East Norway. 144 
 145 
Results 146 
Overall, we were able to retrieve CT scans from 1119 of the 1305 study participants (85.7%). Among these, 147 
688 scans did not include images at the levels of interest or enough of the circumference, or the quality was 148 
too poor for the analyses (Figure 1). Furthermore, 30 patients were excluded due to missing data on SMD 149 
either at the L3 or Th4 level (24 patients) or on relevant baseline characteristics (e.g. height and weight) (6 150 
patients). Thus, 401 patients (30.7%) were included in the present study (Figure 1). The main baseline 151 
characteristics of these patients are presented in Table 1. 220 were men 54.9%); mean age was 66 years; 152 
100 (25%) were younger than 60 years, 79 (19.7%) were 75 years or older; 316 patients (78.8%) had stage 153 
IV disease; and 89 (22.2%) had PS 2. 154 
 155 
Body composition 156 
The mean cross-sectional muscle area (cm2) and the SMI (cm2/m2) of the overall study sample were larger at 157 
the Th4 level than at the L3 level: 176.4 cm2 versus 130.6cm2, and 60.0 cm2/m2 versus 44.5 cm2/m2. Th4 158 
SMD was also higher than the L3 SMD in the overall sample (41.5 HU vs 36.9 HU) both among men (42.0 159 
HU vs. 37.2) and women (40.8 vs 36.5) (Table 2). Comparing men to women, muscle area and SMI were 160 
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significantly larger in men, whereas no significant difference between genders was found for SMD. The 161 
muscle measures were close to normally distributed.  162 
 163 
Agreement between thoracic and lumbar muscle measures 164 
Scatterplots of the Th4 and L3 muscle area (cm2), and Th4 and L3 SMI (cm2/m2) showed a substantial 165 
spread around the lines of complete agreement, indicating only moderate agreement (Figure 2). 166 
 A Bland Altman plot (Figure 3A) investigating the agreement between Th4 and L3 SMI, transformed 167 
into corresponding z-scores, showed no substantial systematic deviation between the two levels and no 168 
substantial difference by gender. There was, however, a considerable spread in the difference between Th4 169 
and L3 z-scores, and the intraclass correlation (single measures) was 0.71 (95% CI 0.64 – 0.77) for men and 170 
0.53 (95% CI 0.41 – 0.63) for women, i.e. consistent with a medium agreement. Regression models 171 
predicting L3 SMI z-scores from Th4 SMI z-scores showed coefficients of 0.71 (95% CI 0.62 - 0.80) in the 172 
male population and 0.53 (95% CI 0.40 - 0.66) among females. The R squares for these models were 0.50 173 
and 0.28 respectively, indicating that the Th4 SMI z-scores were only moderately related to the L3 SMI z-174 
scores.   175 
Regarding the agreement between z-scores transformed from Th4 and L3 SMD, the Bland Altman 176 
plot (Figure 3B) showed results fairly consistent with those for the SMI, except that the spread of differences 177 
was considerably larger. The intraclass correlation (single measures) between Th4 SMD and L3 SMD z-178 
scores was 0.71 (95% CI 0.64 – 0.77) for men, and 0.76 (95% CI 0.70 – 0.82) for women. The regression 179 
models predicting L3 SMD z-scores from Th4 SMD z-scores showed closely similar coefficients for men and 180 
women, 0.71 (95% CI 0.62 - 0.80) and 0.76 (95% CI 0.67 – 0.86), respectively. The R squares for these 181 
models were 0.50 for men and 0.58 for women. 182 
Scatterplots of the actual L3 SMI and SMD plotted against the L3 SMI and SMD recomputed by Th4 183 
SMI by z-scores (Figure 3 B and C) showed a substantial spread of the actual values when compared to the 184 
estimated values.  185 
 186 
Discussion 187 
In this study comparing muscle measures from CT images at both Th4 and L3 levels, using widely accepted 188 
methodology, we found that the muscle area was larger at the thoracic level in both genders. There was also 189 
a substantial difference between the Th4 SMD and L3 SMD, with higher SMD in the thoracic muscle. 190 
Furthermore, the agreement between SMD and SMI at the two levels was only moderate, and for SMI there 191 
was also less agreement between Th4 and L3 among the women than among the men. According to 192 
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regression analyses, z-scores at the Th4 level were not strongly related to L3 z-scores. The agreement 193 
between actual L3 SMI and SMD and the measures recomputed by means of Th4 z-scores was moderate.  194 
 We are aware of only one other study comparing muscle measures at the thoracic- and lumbar 195 
levels in cancer patients. Kim et al. analysed 90 patients with both limited and extensive small-cell lung 196 
cancer, and found poor agreement between pectoral muscle mass at the level above the aortic arch (which 197 
is approximately at the Th4-level) and cross sectional muscle area at the L3 level.25 Though there are 198 
differences in patient populations, software for assessing muscle area, the thoracic level for muscle 199 
assessment, and muscle groups measured, their study support our findings. 200 
Body composition analyses were not a pre-planned part of the RCTs we collected data from. CT 201 
images of the thorax and upper abdomen were mandatory for trial inclusion, but specific requirements for the 202 
CT protocols were not defined in the study protocols. Adequate CT-images at both levels were available for 203 
only 38% of the patients. We anticipated that muscle measures at the Th4 level would be available for the 204 
majority of patients, whereas images at the L3 level would be missing in more cases. As it turned out, a large 205 
number of the Th4 level images were insufficient for muscle analyses. This was mostly due to “cutting of 206 
edges”, i.e. the outer circumference of the muscle mass was missing, or the image quality was not 207 
satisfactory for quantification of muscle mass. Thus, future studies of LBM in cancer patients should include 208 
specific instructions to radiology departments to ensure that body composition can be assessed. 209 
 A strength of our study is the large sample size of patients with similar diagnosis and stage of 210 
disease, though the cohort was too small to allow for subgroup analyses. None of the patients had received 211 
any former systemic cancer treatment, and the study sample included a relatively large proportion of elderly 212 
and PS 2 patients. Thus, although muscle measures could be obtained for only a minority of the targeted 213 
population, we find it reasonable to believe that our findings are representative for advanced NSCLC patients 214 
eligible for first-line palliative chemotherapy. For generalisation of our results, confirmation from other studies 215 
and other cancer populations is, however, necessary. 216 
 CT images at the L3 level include core muscles, such as the rectus abdominis, external and internal 217 
oblique and erector spinae, which are assumed to initiate most full-body functional movement and are 218 
fundamental for stabilizing the body in dynamic movements. Although some of these muscles (erector 219 
spinae) extend into the Th4 level, the major muscles captured at Th4, such as the pectoralis muscles, have 220 
other functions, mainly related to arm and shoulder movements. Their volume and strength may therefore to 221 
a larger extent depend on specific manual activities, and activities that more often apply to men than women. 222 
These functional differences between the muscle groups might contribute to the only moderate agreement 223 
between Th4 SMI/SMD and the L3 SMI/SMD, although the reasons may be more complex. We have not 224 
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found any good explanations in the literature, but a substantial difference in SMD between muscle groups 225 
has formerly been reported.19 We are not aware of any studies investigating whether there is a different 226 
impact of cancer-related muscular depletion between muscle groups. 227 
 The gold standard for measuring LBM is analysing whole body CT or MRI scans. Analyses of single 228 
slices may not predict the LBM correctly, especially in longitudinal studies,29 but is currently the most feasible 229 
approach in larger and multicentre studies of cancer patients. Whole body CT scans are seldom available 230 
unless it is part of specific studies. Thus, such scans were not available from our patients, and it was not 231 
possible for us to investigate whether the Th4 or L3 SMI is in best agreement with the whole body muscle 232 
mass. Further studies are needed to investigate the relationship between Th4 muscle measures and whole 233 
body skeletal muscle mass, and the clinical role of Th4 muscle measures. Until such studies are conducted, 234 
we believe that adequate CT images at the L3 level remains the recommended approach in studies of the 235 
clinical role of muscle measures in cancer patients. 236 
 In conclusion, there is a large variation between the skeletal muscle areas at the Th4 and L3 levels 237 
in patients with advanced non-small-cell lung cancer, and muscle measures at the L3 level cannot be reliably 238 
estimated by transformation of measures at the Th4 level using z-scores. 239 
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Figure 1 Patient selection  385 
 386 
Figure 2  Scatterplot illustrating the agreement between measures at the Th4 and L3 for muscle area 387 
  (cm2), skeletal muscle index (SMI) (cm2/m2) and skeletal muscle radiodensity, for men and 388 
  women separately. A line for perfect agreement has been added to all plots. 389 
 390 
Figure 3 A) Bland Altman plot for the agreement between Th4 SMI and L3 SMI z scores  (with loess 391 
  curves for each gender). B) Bland Altman plot for the agreement between Th4 SMD and L3 392 
  SMD z scores (with loess curves for each gender). C) Scatter plot showing actual L3 SMI 393 
  values and L3 SMI values recomputed from Th4 SMI-scores (by z-scores) (linear fit line for 394 
  overall sample with 95% CI and loess curves for each gender). D) Scatter plot showing  395 
  actual L3 SMD values and L3 SMD values recomputed from Th4 SMI-scores (by z-scores) 396 
  (linear fit line for overall sample with 95% CI and loess curves for each gender).         397 
 398 
Table 1  Baseline characteristics  399 
 400 
Table 2  Body composition measures at the Th4 and L3 levels 401 
Table 1 Baseline characteristics  
 
 





Age Mean (range) 66 (37-90) 68 (37-90) 64 (37-85) 
 ≥ 75 years 79 19.7% 48 21.8% 31 21.0% 
Histology Squamous cell carcinoma 92 22.9% 64 29.1% 28 15.5% 
 Adenocarcinoma 217 54.1% 104 47.3% 113 62.4% 
 Other 92 21.0% 52 23.7% 40 22.1% 
Disease stage IIIB 85 22.9% 47 21.4% 38 21.0% 
 IV 316 78.8% 173 78.6% 143 79.0% 
Performance status 0 80 20.0% 46 20.9% 34 18.8% 
 1 232 57.9% 122 55.5% 110 60.8% 
 2 89 22.2% 52 23.6% 37 20.4% 
Body weight, kg, mean (SD) 69.0 (13.8) 73.7 (11.9) 65.1 (13.1) 
Body Mass Index, kg/m2, mean (SD) 23.9 (3.9) 23.8 (3.4) 23.9 (4.5) 
Appetite loss Yes 211 52.6% 113 51.4% 98 54.1% 
 No 190 47.4% 107 48.6% 83 45.9% 
 
Table 2 Body composition measures at the Th4 and L3 levels 
 
 














  Mean SD Mean SD Mean SD  Mean SD Mean SD Mean SD  
Measured muscle area, cm2 176.4 39.6 200.7 31.7 147.0 25.8 < 0.001 130.6 29.2 149.0 23.4 108.2 17.5 < 0.001 
Skeletal muscle index (SMI), cm2/m2 60.1 10.9 65.0 10.1 54.1 8.8 < 0.001 44.5 8.1 48.3 7.7 39.8 6.0 < 0.001 
Skeletal muscle radiodensity (SMD), HU 41.5 6.9 42.0 6.8 40.8 6.9 0.107 36.9 8.4 37.2 7.9 36.5 9.0 0.357 
  
*p-value for the comparison between men and women 






























*Whole cross sectional area not included; or too poor image quality  
**Lack of images at the L3-level; whole cross sectional area not included in the images; or image-quality too poor 
*** Either of the above 
     CT images not received (n=186) 
                    RCT 1 (n=174) 
                    RCT 2 (n=    0) 
                    RCT 3 (n=  12) 
CT images at the L3 level not 
analyzable ** (n=130) 
                    RCT 1 (n=37)                                   
                    RCT 2 (n=51) 
                    RCT 3 (n=42) 
CT images at both Th4 and L3 
not analyzable *** (n=218) 
                    RCT 1 (n=59) 
                    RCT 2 (n=97) 
                    RCT 3 (n=62) 
 
     All patients (n=1305) 
                    RCT 1 (n=432) 
                    RCT 2 (n=436) 
                    RCT 3 (n=437) 
     CT images collected (n=1119) 
                    RCT 1 (n=258) 
                    RCT 2 (n=436) 
                    RCT 3 (n=425) 
     Eligible for analyses (n=401) 
                    RCT 1 (n=  73) 
                    RCT 2 (n=147) 
                    RCT 3 (n=181) 
CT images at the Th4 level 
not analysable* (n=340) 
                    RCT 1 (n=  85)                         
                    RCT 2 (n=122) 
                    RCT 3 (n=133) 
     TH4 and L3 analyses conducted, (n=428) 
                    RCT 1 (n=  77) 
                    RCT 2 (n=166) 
                    RCT 3 (n=188) 
Missing data on muscle radiodensity at 
either L3 (n=7) or Th4 (n=13) or both 
(n=4) and relevant baseline data (3) 
                    RCT 1 (n=4) 
                    RCT 2 (n=17) 
                    RCT 3 (n=6) 
Figure 2  Scatterplots illustrating the agreement between measures at the TH4 and L3 for muscle area (cm2), skeletal muscle index (SMI) (cm2/m2) 
  and skeletal muscle radiodensity, for men and women separately. A line for perfect agreement has been added to all plots. 
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Figure 3 A) Bland Altman plot for the agreement between Th4 SMI and L3 SMI z-scores (with 
  loess curves for each gender). B) Bland Altman plot for the agreement between Th4 
  SMD and L3 SMD z-scores (with loess curves for each gender). C) Scatter plot  
  showing actual L3 SMI values and L3 SMI values recomputed from Th4 SMI-scores (by 
  z-scores) (linear fit line for overall sample with 95% CI and loess curves for each  
  gender) D) Scatter plot showing actual L3 SMD values and L3 SMD values recomputed 
  from Th4 SMI-scores (by z-scores) (linear fit line for overall sample with 95% CI and 
  loess curves for each gender). 
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